ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

被引：1
|
作者：
Bailleux, Caroline
Bachelot, Thomas
Bidard, Francois-Clement
Hardy-Bessard, Anne-Claire
Bieche, Ivan
Pradines, Anne
Clatot, Florian
Rouge, Thibault De La Motte
Canon, Jean-Luc
Pistilli, Barbara
Chang, Kyle
Quinn, Katie J.
Gustafson, Heather L.
Dalenc, Florence
Foa, Cyril
Ammarguellat, Hanifa
Bernard-Marty, Chantal
Lucas, Brigitte
Barthier, Sophie
Lorchel, Fabrice
Gisserot, Olivier
Arnould, Laurent
Mauduit, Marjorie
Lemonnier, Jerome
Berger, Frederique
Delaloge, Suzette
Andre, Fabrice
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [42] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [43] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [44] PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Fusco, Nicola
    Malapelle, Umberto
    Fassan, Matteo
    Marchio, Caterina
    Buglioni, Simonetta
    Zupo, Simonetta
    Criscitiello, Carmen
    Vigneri, Paolo
    Dei Tos, Angelo Paolo
    Maiorano, Eugenio
    Viale, Giuseppe
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
    Magno, Elizabeth
    Bussard, Karen M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [46] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer
    Wong, Vanessa
    de Boer, Richard
    Baron-Hay, Sally
    Blum, Robert
    Boyle, Frances
    Chua, Susan
    Clarke, Kerrie
    Cuff, Katharine
    Green, Michael
    Lim, Elgene
    Mok, Kelly
    Nott, Louise
    Nottage, Michelle
    Tafreshi, Ali
    Tsoi, Daphne
    Uccellini, Anthony
    Hong, Wei
    Gibbs, Peter
    Lok, Sheau Wen
    CLINICAL BREAST CANCER, 2022, 22 (08) : 792 - 800
  • [48] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
    Hortobagyi, Gabriel N.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Chan, Arlene
    Nusch, Arnd
    Yap, Yoon Sim
    Hart, Lowell
    Favret, Anne
    Marschner, Norbert
    Sonke, Gabe S.
    Ohnstad, Hege Oma
    Arteaga, Carlos
    Su, Fei
    He, Wei
    Miller, Michelle Kristine
    Stemmer, Salomon M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
    Kovac, Anja
    Kuhar, Cvetka Grasic
    Ovcaricek, Tanja
    Matos, Erika
    Mencinger, Marina
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345